October 2025 - Corcept Therapeutics

ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor

October 19, 2025

Lorusso et al. • 2025 • ESMO

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

October 18, 2025

Lorusso et al. • 2025 • ESMO

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

October 9, 2025

Andrews, et al. • 2025 • NEALS 2025